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The gene encoding glycoprotein B (gB) of murine cytomegalovirus (MCMV) strain Smith was identified,
sequenced, and expressed by recombinant vaccinia virus. The gB gene was found adjacent to the polymerase
gene, as it is in the genome of human cytomegalovirus (HCMV). The open reading frame consists of 2,784
nucleotides capable of encoding a protein of 928 amino acids. Comparison with gB homologs of other
herpesviruses revealed a high degree of homology. The similarity between the MCMV gB and the HCMV gB is
most prominent, since 45% of the amino acids are identical. In addition, all cysteine residues are at homologous
positions, indicating a similar tertiary structure ofthe two proteins. In contrast to HCMV, theMCNV gB mRNA
is a true late transcript. A recombinant vaccinia virus expressing the MCMV gB gene has been constructed
(Vac-gB). Antibodies raised against the Vac-gB recombinant precipitated proteins of 130, 105, and 52 kDa from
MCMV-infected cells. The identity of the MCMV gB with the major envelope glycoprotein ofMCMV described
by Loh et al. was shown (L. C. Loh, N. Balachandran, and L. F. Qualtiere, Virology 166:206-216, 1988).
Immunization of mice with the Vac-gB recombinant gave rise to neutralizing antibodies.
Murine cytomegalovirus (MCMV) and human cytomega-
lovirus (HCMV) are members of the subfamily Betaherpes-
virinae. HCMV is a ubiquitous human pathogen, but most
primary infections do not lead to an apparent disease.
However, HCMV is a major cause of serious illness in
congenitally infected infants and in immunocompromised
individuals (15, 34). Patients with AIDS, organ allograft
recipients, and cancer patients receiving immunosuppres-
sive drugs develop severe and often fatal HCMV infections.
At present only live, attenuated virus strains which still bear
the risk of latent infections are available as vaccines. The
severity of the CMV infection may be moderated by the
administration of anti-CMV antibodies (37). The efficacy of
the vaccines and the value of the antibody treatment are
controversial (41). A better characterization and understand-
ing of the host immune response against CMV would facili-
tate the search for new and improved vaccines and targeted
treatments.
Envelope glycoproteins of herpesviruses represent domi-
nant antigens for both the cellular and the humoral immune
response (40). Their property of serving as targets for
neutralizing antibodies is of particular interest. The major
envelope glycoprotein complex ofHCMV is called gC-I (16).
The glycoprotein complex gC-I consists of two mature
glycoproteins with molecular masses of 93 to 130 kDa and 52
to 58 kDa, derived by proteolytic cleavage from a precursor
glycoprotein of 150 to 170 kDa (4, 9, 38). The proteins are
encoded by a gene referred to as gB by Cranage et al. (9) and
Mach et al. (30) because of its sequence homology with the
glycoprotein B (gB) gene of herpes simplex virus (HSV). A
significant fraction of the neutralizing antibodies in human
antisera are directed against the proteins of the gC-I complex
(4). In addition, antisera raised against vaccinia virus recom-
binants expressing gB or monoclonal anti-gB antibodies
effectively neutralize the virus in vitro (9). These data
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suggest that the glycoprotein B is an important target for the
humoral immune response against HCMV.
Due to the species specificity of HCMV, in vivo experi-
ments cannot be conducted. Therefore, the availability of an
appropriate animal model is important. MCMV has been
useful for studying CMV infections because of the many
similarities between MCMV and HCMV in biology and
pathogenesis. Thus, the study of the murine immune re-
sponse to MCMV may be valuable for understanding the
situation in humans.
In this report, we describe the identification and sequenc-
ing of a gene whose primary translation product shows
characteristics of a glycoprotein. Comparison of the deduced
amino acid sequence of the protein with sequences of other
herpesvirus glycoproteins reveals extensive homology to the
glycoprotein B of HCMV. The gB gene was expressed by
recombinant vaccinia virus. The Vac-gB recombinant in-
duced neutralizing antibodies in mice and thus provides a
tool to test the usefulness of a gB subunit vaccine in an
animal model.
MATERIALS AND METHODS
Virus and cell culture. MCMV (mouse salivary gland virus
strain Smith [ATCC VR-194]) was propagated on BALB/c
mouse embryonal fibroblasts as described previously (18).
CV-1 cells, used for the propagation of vaccinia viruses,
were maintained in Dulbecco's modified Eagle medium
supplemented with 10% (vol/vol) fetal calf serum, 2 mM
L-glutamine, 100 ,ug of streptomycin per ml, and 100 U of
penicillin per ml. Mouse embryonal fibroblasts were MCMV
infected with 20 PFU per cell by using the technique of
centrifugal enhancement of infectivity at 800 x g for 30 min.
Cell proteins were labeled with 125 ,uCi of [35S]methionine
(Amersham, Braunschweig, Germany) per ml of methionine-
free medium.
Sequence analysis. The 5'-terminal part of the gB nucleic
acid sequence (nucleotides [nt] -20 to 1400) was determined
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FIG. 1. Localization of the glycoprotein B coding region. Shown
are Hindlll cleavage map of the MCMV (Smith) genome (top) and
restriction enzymes sites used for gB gene characterization and
cloning purposes (middle). The black bar represents the hybridiza-
tion probe used in the Northern blot experiment. ORFs and plas-
mids used for cloning purposes are indicated by open arrows and
lines, respectively.
by a modified version of the dideoxy sequencing method (42)
using Bal 31- and exonuclease III-generated subclones of the
3.5-kb PvuII fragment (Fig. 1, p3.5). The 3'-terminal part of
the nucleic acid sequence (nt 1400 to 2300) was obtained by
the method of Maxam and Gilbert (32) with modifications
reported previously (19). Both strands were sequenced, and
overlapping clones were used to confirm the sequence. The
Genetics Computer Group software package version 7.0
from April 1991 (10) was used for the analysis of the nucleic
acid sequence, for the deduction of the amino acid sequence,
and for the prediction of the secondary structure of the gB
protein. The herpesvirus gB amino acid sequences from the
GenBank data base (release 69 from September 1991) were
compared.
Northern blot (RNA) analysis and nuclease protection. At
different time points postinfection, whole-cell RNA was
prepared from MCMV-infected cells and mock-infected con-
trol cells following published procedures (7). The RNA was
size fractionated by gel electrophoresis, transferred to nitro-
cellulose filters, and hybridized to a gB-specific, 32P-labeled
DNA probe. For the S1 analysis, whole-cell RNA was
hybridized to 32P end-labeled DNA fragments and digested
with nuclease S1 as described previously (19). Nuclease-
resistant fragments were size fractionated on denaturing
sequencing gels.
Rapid amplification of cDNA ends. The 3' end of the gB
mRNAs was determined according to the protocol of
Frohman et al. (14) with the oligonucleotides (dT)17-R1-RO
(5'-AAGGATCCGTCGACATCGATAATACGACTCACTA
TAGGGATTTTTTTTTTTTTTTTT-3'), RO (5'-AAGGATC
CGTCGACATC-3'), and gB.End (5'-CAGAATTCGTATC
TCATCTTCACGAGGC-3'). The primer gB.End corre-
sponds to positions 2650 to 2669 in Fig. 2.
Production of recombinant vaccinia viruses. Vaccinia virus
recombinants expressing a truncated (Vac-gB626) and the
complete (Vac-gB) gB open reading frame (ORF) were
generated. For the construction of the recombination plas-
mid pCS-gB626, a 3.5-kb PvuII subclone (Fig. 1, p3.5) of the
HindIII-D fragment (12) constituting two-thirds of the gB
ORF and 1.6 kb of upstream sequences was digested with
SmaI, which cleaves in front of the first ATG, and a BamHI
linker was added. Then, the ORF encoding 626 amino acids
(aa) of the gB protein was isolated by digestion with BamHI
and inserted into the vaccinia virus recombination vector
pCS43 (1) downstream of the vaccinia virus early-late pro-
moter p7.5.
Attempts to clone the complete gB ORF into a multicopy
plasmid were not successful. Therefore, the gB ORF orig-
inally cloned in the low-copy-number plasmid pACYC177
was flanked with the vaccinia virus thymidine kinase se-
quences and the vaccinia virus p7.5 promoter. In detail, the
HindIII-D fragment cloned into pACYC177 (12) was di-
gested with EcoRI and religated, thereby removing nearly
the complete HindIII-D fragment sequences upstream of the
gB gene and also part of the gB ORF. Sequences down-
stream of the gB gene and 600 bp of the vector pACYC177
were removed by digestion with DraIII, and religation
resulted in the plasmid pDra (Fig. 1). The gB ORF was
restored by insertion of a 1.3-kb HindIII-XbaI fragment from
a PstI-XbaI subclone of the HindIII-D fragment (Fig. 1,
pl.3). This step also removed the remaining HindIII-D
fragment sequences upstream of the gB gene. The resulting
plasmid was named pACYC-gB. The sequences constituting
the 5' end of the vaccinia virus thymidine kinase gene and
the vaccinia virus p7.5 promoter from the plasmid pGS62 (9)
were inserted as a 1.2-kb Hindlll-Smal fragment upstream
of the gB ORF after digestion of pACYC-gB with HindIlI
and SmaI. The sequences constituting the 3' end of the
vaccinia virus thymidine kinase gene were derived from
plasmid pCS43 and inserted as a 1-kb HindIII-SmaI frag-
ment downstream of the gB ORF and the vector sequences.
Consequently, the vaccinia virus recombinant Vac-gB con-
tains the gB ORF and 3.5 kb of pACYC177 vector sequences
downstream of the p7.5 promoter. The vaccinia virus recom-
binants were produced by following established procedures
(31) using the DNA of vaccinia virus strain Copenhagen and
the temperature-sensitive mutant ts7 (11).
Preparation of antisera and immunoprecipitation. Antise-
rum from latently MCMV-infected BALB/c mice was used
for the detection of the gB protein in Vac-gB-infected cells.
A gB-specific antiserum was prepared by infection of rabbits
with the vaccinia virus recombinant Vac-gB626. Another
gB-specific antiserum used for neutralization assay was
prepared by infection of mice with the Vac-gB recombinant.
The monospecific rabbit serum was used to identify the
glycoprotein B in MCMV-infected cells. Immunoprecipita-
tions were performed as described previously (20). In brief,
samples of cell lysates were incubated with S ,u of antiserum
or ascitic fluid. A 50% protein A-Sepharose suspension
(Pharmacia) was preincubated with rabbit antibodies specific
for mouse immunoglobulin G (Dianova) before addition to
the antigen-antibody complexes. The precipitated proteins
were separated by sodium dodecyl sulfate-7.5% polyacryl-
amide gel electrophoresis.
MCMV neutralization assay. The neutralizing activity of
gB-specific mouse antisera was determined by a plaque
reduction assay on mouse embryonal fibroblast monolayers
grown in 48-well flat-bottom plates. Serum samples were
heated at 56°C for 30 min to inactivate serum complement. A
400-,ul volume of the serum dilutions was incubated at 37°C
for 30 min with 400 PFU of MCMV contained in 50 pul of
medium. Then, 50 pul of rabbit complement was added, and
after incubation for another 30 min at 37°C, the plaque assay
was carried out.
Nucleotide sequence accession number. The GenBank ac-
cession number for the nucleotide sequence reported in this
article is M86302.
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gtcgcactaT ATAAcgagac gttcggcaag cagttg4cCt tqtqqcqcgt cqaqqacqqc gatqaqatcq qcgacggaat
aaTATTAAcg tacaatccag aatctccqtt uatcct6cgt cqcqqaqatc Qaaattaca4 atccaggaat ctqtacttqc
tqctctacaa qcatctctcq qtcqactccq agactctcqc cgacgccqqt tctcqcqcct cqqtcqccqa cttatqtcaa
qtcqaqaqac ccqqqccqat cqctqaacaa cqctcqtcaa cgca4aATGT CA6A6AAGAA CGAAAGAG6A TGTCGCTCCT
CGAGCTGGTA CGCGATGTCG ACGGCGCTGG C6GTGACGAT CTGGTGCCTC CTTGCCTGTA CAAGTGAGGT AATCGCGGCG
GCGAGTACAC CAGGTACTAC TCCGAAAGCA AAAACTGACA CTTCGTCAGA AACCGCGTCC GCA6AAACAG A6ACGGCGAC
TTCGGGCGCG GCGACCGGAA AGAAG6AAGC CAC6CCGACT CAGGCCTCGA AGATAACGGG GACCACCATC GTTCCCTTCG
TAAACGAGAC GGAGGACATG GTTTCTGTTG ACATA6ATAA ATATCCTTAC AGAGTGTGCA TGGCTGTGTC TACTGATCTC
GTTCGGTTCG GGAAAAGTAT A6ATTGTATC AATCATACCC CGAAGACACC CGTACAAGAG GGGATCATGG TAGTTTACAA
AGAAAATATC GTGGCTTACA CGTTTGAGGT 6ATCACTTAT CACAAAGATG CGATCTTTCA 66AAAGTTAT GCTGACACGA
CTACTAATTA TTTCTTGGGG ACTAGCGTGA CT6AAATG6C CTTCCCCATC TGG6GACTGG ATGAGGTAAA CAGAAACAAC
AGGTGTTACT CTGCCGC6AG TAG6ATACTC AATGGGGAAG TGTATGTCGC TTACCACGAA GATAGCTATA GGAACTATAC
TATGGTGCTT GTGGAGGATG ATTACAGGAG TAAGAACAGT AA6CGATACG TGACCACCAA GA6TAGGTAT CATAAGGGCG
CTTGGACGTG GAGATACACC GAATCCTGTA ACATGAACTG CGTCGTCGTC GTCACGAAAG CTAGGTCTAA CACCCCCTAC
GAATTCTTCG TGCTCAGCTC CGGG6AAGTC GTCGAGATAT CACC6TTTTA CAAC6GTGAA AACTCCGAGC CCTTCGAAGA
GGACACGAGA AATTTCTGGA TTCGCAAGAA TTACACCATG AGACGTACT TCGGTGMACT CGCGGCACCC AAAAAAGTAG
TACCTCTGAT GGCTTTTCTA 6AGAGG6G66 ACAT6ACCAT CGGGTGGGAG ATCTTTCCCA AACA6AATGT CACGTGCGAC
TGGAAGAAAT GGCAGACGGT TTC6AGG6CG ATACGCACTG ACACCAATAC TGGCTATCAT TTT6TTTCCA AGGGTTTAAC
TGCTACTTTT GTGGCCAGTA MACGCAAAT AGATTATAAT ACTACTACCG AAGGTAAAAA TTATAACACC TTCCGATGTG
TTTATGATGA GTTTGTAGAA GAAGTGAATC GTGT6TTT6A AGATGAGTAC AATGAGACGC ATGTGAAAGA CG6G6AGCTT
GAAATGTATA GAACAACGGG AGGTCTTATT GTATTGTGGC AGG6ATT6AA AGCGAAATCA CTGCATAATC TGGAAAAATT
TGCCGCGTTG AATAACGTTT CAGTGGCGAC TGCTA6CCCT CCTGTAACCA CTGCCGCGAC TGAGAATGGT ACTACTGTTC
GTTCTCGCCG AAAACGCAGC TTTGACAACC TAGATGATGT GGTGACGGAT ATCAGCTATG CTCAACTGCA ATTTACCTAC
GACGTGCTCA AGGACTACAT CAACGATGCG CTCCGAAACA TCATGGACGC TTG6TGTCGC GACCAGAAAC GGACGGCGGA
GATGCTCAAG GAGCTCAGTA AGATCAATCC GTCCAACATC TTGTCGGCCA TCTACGAGAG ACCGGTCACC 6CCAAGCTGG
CGGGCGACGT CATCGCGATG TCCGAGTGT6 TCAAGGTCGA TCAGAGTAGT GTGA6GGTCC T6AA6GACAT GCGGATCTTC
CAGGACGGGA AGGTC6TCAA CTGTTATTCG A6ACCGCTGG TCGTCTTTCA GTTCATCAAC TC6ACGMGC TC6AGTCGGG
CCAGCTGGGC GAGAACAACG AGATCATGCT 66GCACCTTT CGGACGGAGA ACTGCGACAC GAACAGCAGG AA6ATCTTCG
TCGTGGGGAC TGTGGGCTAC GAGTATCGGG ACTACCGTTT CAGGAACGTG ACCAGTCTGG AGCACATCGA CCTCGTCGAC
ACCCTGATCG GGCTGGACAT CGAGCCCCTG GAGAACACCG ACTTCAAGGT GCTCGAGCTG TACTCGAAGG 6AGAGCTGCG
CGCCTCGAAC GTGTTCAGCC TGGAC6AGAT CATGC6GGA6 TACAACTCGC AGAAGCAGCA CATCCGCACC CTGAGCGCCA
AAGTCAACGA CAACACGCCC TCTTATCTCT TGGGGTTGGA TACTTTCATG CAGGGGCTAG GGGTCGCGGG TAAGGGGATC
GGGGTGGCCA TCGGG6CCGT CGGCGGGGCC GTGTCTTCGG TGGTGAACGC CGTCACGGGC TTCCTGACGA ACCCGTTTGG
AGGTTTCACC ACCATCCTCC TGGTGATCGG CGTGCTAGCC GTCGTGTATC TCATCTTCAC GAGGCCG6TC GAGTACTTCT
TCCCCTACGC CACCCAGACC GCCGTGCAGT ATGCTCCTCC CGGCGGCGCG CACGGGGGAC TCGAGA6CGG GCCGCCGGGA
GCGCCTGGTC TGCATCGGCG CGTGAACGCG GGCGGCAGTG ACGATTCGGG TAAGGCGTGG ACTAGCGATA AAMGGGCTT
GGAGAGGACC TACACCGAGC AA6GATGCTCT ATTGATACTC CGCGCGTTMA AACAGCTAGA CGACA6CCAA C6CAACGAGA
AAGCGCAGCA GAAAGCGACT AGACTGCCGA CGGGCATCTT GGACCGTCTC MAMGGTAACG ACACCAGTG6 CTACCAGCGA
TTACCGGCGG AGGACTCCGA TTTCGAGTAC tqacggccoa catqqacact tqcqtqqaqa ctttcttcaa cccctacctq
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-gacgqaaac cccqtcqcqa ttqqaqacqc tqcqaqqata atAATAAAaa ctttttacaa utcgttccgc gtggCGTGTT 3164
GTatgatggt gcgacggggt tAATAAAggt acagtccggc atggaaccca gGATGTTCTa cgccgagaaa gagtacgtgc 3244
FIG. 2. Nucleotide sequence of the gB gene. The nucleotide
sequence from 36 nt upstream of the first 5' cap site to 54 nt
downstream of the second polyadenylation signal of the gB mRNA
is shown. The termini of the mRNAs are marked with asterisks. The
TATA box sequences, the polyadenylation consensus sequence,
and the 3' end YGTGTTYY consensus sequences are printed in
boldface type. The predicted ORF of the mRNA is underlined and
set in boldface capital letters. The Smal site at map unit 0.371 is
overlined for orientation.
RESULTS
Nucleotide sequence of the glycoprotein B gene. The loca-
tion of the glycoprotein B (gB) gene is conserved throughout
all herpesviruses. A conserved gene block contains the
genes for the major DNA-binding protein, a putative trans-
port protein, the glycoprotein B, and the viral DNA poly-
merase (23). Assuming colinearity between the MCMV
genome and the genomes of other herpesviruses, especially
HCMV, the putative MCMV gB homolog was expected to
be located within the MCMV HindIII-D fragment upstream
of the polymerase gene (Fig. 1) (17). Sequencing of this
region revealed a single, long ORF of 2,784 nt (Fig. 2)
extending from the ATG codon at positions 250 to 252 to the
termination codon at positions 3032 to 3034. The nucleotide
sequence of the gene showed 59% homology to the glyco-
protein B gene of HCMV.
Expression kinetics of the gB gene. The MCMV replication
cycle is divided into three phases: immediate-early, early,
and late. Some genes for structural proteins are already
expressed in the early phase, other genes are transcribed
early and translated in the late phase, and true late genes are
only expressed after the onset of the viral DNA replication.
To determine to which class the gB gene belongs, RNA from
Ado t. >D\N t oSC nV f
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FIG. 3. Transcriptional analysis of gB gene expression kinetics.
RNA was prepared at different times postinfection and analyzed by
Northern blot hybridization with a gB-specific probe. Lane 1 con-
tained RNA from uninfected cells. Lanes 2 through 6 contained
RNA prepared from infected cells at different times p.i. Lanes: 2, 2
h; 3, 4 h; 4, 8 h; 5, 16 h; 6, 24 h. Lane 7 contained RNA isolated from
cells infected in the presence of phosphonoacetic acid (PAA) for 24
h.
infected cells was prepared at different times after infection,
and a Northern blot hybridization was performed. A 32P-
labeled 652-nt EcoRV fragment (Fig. 1) from the middle of
the gB ORF was used to detect the transcript(s) of the gB
gene. One major transcript was visible at 24 h postinfection
(p.i.) (Fig. 3, lane 6). On the basis of the size of the gB
mRNA predicted from the nucleotide sequence, the 3.3-kb
transcript is expected to represent the gB mRNA. In addi-
tion, two bands of higher molecular masses, which show the
same expression kinetics as the 3.3-kb mRNA, were visible.
The gB-specific transcript of 3.3 kb appeared at 16 h p.i.
(Fig. 3, lane 5) but was not visible at 8 h p.i. The late phase
of the MCMV gene expression starts at 16 h p.i. (18). After
addition of the DNA polymerase inhibitor phosphonoacetic
acid to infected cells, no gB-specific transcript could be
detected (Fig. 3, lane 7). Thus, the transcription of the gB
gene is restricted to the late phase of infection.
Identification of the 5' and 3' ends of the gB transcript(s).
Nuclease SI analysis was performed to determine the 5' and
3' ends of the gB transcript(s). To map the position of the 5'
end of the gB mRNA, a 465-nt fragment was used (Fig. 4A,
lane 1). This fragment includes 451 nt of viral sequences
extending from an HpaI site (map unit 0.378) to the SmaI site
(map unit 0.375) (Fig. 1) and 14 nt of vector sequences in
front of the HpaI site. The 465-nt fragment was 5' end
labeled at the SmaI site. After hybridization of the fragment
to RNA isolated from infected cells in the late phase of
infection, two nuclease Si-resistant fragments of 135 and 213
nt were visible (Fig. 4A, lanes 3 and 4). This result indicates
two different start positions of transcription, 23 and 29 nt
downstream of two TATA boxes (Fig. 2, positions -27 to
-23 and 47 to 52). The additional protected fragment of 451
nt corresponds exactly to the full length of the viral se-
quences and results from protection by a transcript of an
overlapping gene (33a).
For the location of the 3' end of the gB mRNAs, a
SalI-Stul fragment (map units 0.366 to 0.361; Fig. 1) was
used for SI nuclease analysis (Fig. 4B, lane 1). The 1,201-nt
fragment was 3' end labeled at the Sall site. A protected
fragment of approximately 870 nt was found (Fig. 4B, lanes
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FIG. 4. Structural analysis of the gB gene. The 5' (A) and 3' (B)
ends of the gB transcripts were determined by nuclease SI analysis.
Lanes 1 show the labeled fragments before the nuclease treatment,
and lanes 2 show nuclease-resistant fragments after hybridization to
mock RNA. Lanes 3 and 4 show protected fragments after hybrid-
ization to RNA of late-phase infected cells at 52 and 58°C, respec-
tively. 5'-end-labeled HpaII cleavage products of pBR322 and the
123-bp and 1-kb ladders (GIBCO BRL) served as size markers. To
present all relevant information in one figure, the autoradiographs
were cropped and refitted.
3 and 4), indicating that the two gB transcripts have a
common 3' end. Two putative polyadenylation signals (po-
sitions 3127 to 3132 and 3186 to 3191) were found in the
nucleotide sequence (Fig. 2) (13). The sequences CGTGT
TGT and GATGTTCT (positions 3159 to 3166 and 3216 to
3223), 27 and 25 nt, respectively, downstream of the poly-
adenylation signals, show homology to the consensus se-
quence YGTGTTYY, which is frequently found downstream
of mRNA 3' termini (33). The protected fragment of 870 nt
locates the 3' end of the gB mRNAs between the first
polyadenylation signal and the first YGTGTTYY signal. The
two smaller protected fragments (Fig. 4B, lanes 3 and 4)
probably result from overdigestion of the DNA-RNA hy-
brids due to insufficient hybridization as a consequence of
AT-rich sequences around the polyadenylation signal. To
determine the 3' ends of the gB mRNAs more precisely,
cDNA was synthesized from the gB mRNAs. The 3' ends of
the cDNAs were amplified according to the protocol of
Frohman et al. (14) by using the primers Rl and gB.End. The
amplified fragment of approximately 550 nt was cloned into
pUC19 and subjected to sequence analysis. According to the
sequence data, the 3' end of the gB mRNAs is located at the
C residue at position 3147 (Fig. 2), 15 nt downstream of the
first polyadenylation signal. There is no indication that the
second polyadenylation signal is also used. Therefore, we
conclude that the mRNAs stop predominantly after the first
polyadenylation signal.
Primary amino acid sequence and secondary structure
analysis of the MCMV glycoprotein B. The amino acid
sequence of the MCMV glycoprotein B was deduced from
1 I8 RNE GC SSSWYA ST A L A V T I WCLLACT8E I A
IME S R - - - - V V - V N L C - V C L G 20
38 I P G T T P A K TT ST E T A B A E T e T A T 8 G A A T G K
--V Sl S S S - S H - T S S - ti N G S H T - R - T --Q - R S V Y - Q H V - S S 60
73 K E A T P T Q A 8 K I T G T T I V P F V N E T E D V S V D I D K Y P Y R VC
E A V S H R A N E T - YN-- L K Y G - V - G - N T T - - - - - - - S 95
112 8 A V 8 T D L V R F G K 8 I D C I iON T P K T P V Q E G I N V V Y K E N I V A
- - Q G --- I - - E R N - I - T S M K - I N E D L D
-
- - - - - - R - - - 135
151 Y T F E V I T Y H K D A I F Q R 8 Y A D T T T N Y F L G T S V T KN A F P IW
H --K - R V - Q -V L T - R - - - - Y I Y - T - L --S N T E Y V - P - M --175
191 L D E V N R N N R C Y 8 A A B R I L N G E V Y V A Y H E D B Y R N Y T H V L V E
IH H I - K F A Q -
--S Y - -V I G- T - F - - - - R - - - E K - Q - I P 215
231 D D Y R K N S K R Y V T T K 8 R Y H X G A W T W R Y T E 8 C N NCV V V V T
---S N T H - T - - - - V - DQ W -S R G S - - L - R- T --L --M L T I - 255
271 K A R 8 N T P Y E F F V L 8 8 G E V V E I S P F Y N G E N 8 E P F E E D T R
T - - - K Y - - H - - A T - T - D - - Y - - - - - - - T - R N A S Y - G - N A D 295
309 N F W I R K N Y T N K T Y F G E L A A P K K V V P L M A F L 2 R E D M T I Q W E
K- F - F P - - - I V S D
--RP N -A P E T H R -V - - - - - A - S V - S - D 335
349 IF P K Q N V T C DW K KW Q T V 8 R A I R T D T N T G Y H F V S K G L T A T F
- Q D E - - - - Q L T F - E A S E - T
--S E A E D S - - - S - A K M - - - - 375
389 V A S K R K I D Y N T T T E G K N Y N T F R C V Y D E F V E E V N R V F E D E Y
L S K - Q E V N M S D S A L D - - R - - A I N K L Q Q I - N Ts - 408
429 N E T H V K D G E L E X Y R T T G G L I V L W Q G L K A K 8 L H N L E K F A A L
- O - Y E - Y - N V S V F E - S - - - V - F - - - I-Q---V E --R L -NR448
469 N N V 8 V A T A 8 P P V T T A A T E N G T T V R 8 R R K R 8 P D N L D D V V T D
SS L N I T H R T R R S - S D -N -H L - - M E S V H N L 479
509 I 8 Y A Q L Q F T Y D V L K D Y I N D A L R N I M D A W C R D Q K R T A EN L K
-
- - - - - - - - T - R G - - - R - - A Q - A E - - - V - - R - - L - V F - 517
549 E L 8 K I N P 8 N I L 8 A I Y E R P V T A K L A G D V I A M8 E CV V D Q 8 8
-
- - - ---- A - - - - - -N K -IA - R F M - - - LG L A S -T I N - T - 557
589 V K V L K D NR I F Q D G K V V N C Y 8 R P L V V F Q r I N 8 T K L Z 8 G Q L G
----R --N V K E S P G R - - - - - V - I - N - A --S Y V Q Y - - - - 595
629 E N N E I M L G TF R T E N C D T N 8 RK I F V VG T V G Y E Y R D Y RF RN V
-D - - - L --N H - - - E - Q L P - L - - - I A - N S A - - - V --L - K R M 635
669 T 8 L E H I D L V D T L I G L D I E P L E N T D F K V L E L Y 8 K G E L R A S N
I D - S S - S T - - S M - A - - - D - - - - - - - R - - - - - - Q K - - - 5 - - 675
709 V F 8 L D E I N R E Y N 8 Q K Q H I R T L 8 A K V N D N T P 8 L L G L DT F H
-
- D - E - - - - - F - - Y - - R V K Y V E D - - V - P L - P |- - K - - - D L - 715
749 Q G L G V A G K G I G V A I G A V G G A V 8 8 V V N a v T G F L T N P F G G F T
S - - - A - - - A V - - - - - -
---
- - - A - - - E G -Ah T - - K - - - - A - - 755
789 T I L L V I G V L A V V Y L I F T R P V E Y F F P Y A T Q T
I - - V A - A - V I I T - - - Y - - Q R R L C T Q - L Q N L - - - L V S - D G - 795
819 A V Q Y A P P R G A H G G L E 8 G P P G A P G L H R R V N A G G 8 D D 8 G K A V
T - T S G S T K D T S L Q A P - S Y E E S - Y N S - R K G P - P P 828
859 T 8 D K K G L E R T Y T E Q D A L L I L R A L K Q L D D 8 Q R N E K A Q Q K A T
S - - A S T A A P P --N E Q - Y Q M - L - - A R - - A E - - A Q Q N G TD S L 868
899 R L P T G I L D R L K G N D T 8 G Y Q R L P a E D S D F E Y
D G Q - - T Q D K G Q K P N L - - - - R H R K N - - R H - K D S - E E E N V 906
FIG. 5. Comparison of the deduced amino acid sequences of the
MCMV (top lines) and HCMV (strain AD169; bottom lines) gB
homologs. The sequences are displayed in the one-letter amino acid
code. Spaces were inserted for maximal alignment of homologous
amino acid sequences. Identical amino acids are marked with dashes
in the HCMV sequence, and potential N-linked glycosylation sites
are over- or underlined. The putative signal sequence and trans-
membrane region are boxed. Cysteine residues of the MCMV gB are
marked with asterisks. The putative proteolytic cleavage sites are
indicated by arrows, and the cleavage signal sequences are under-
lined twice.
the nucleic acid sequence of the identified ORF (Fig. 5).
Hydrophobic and hydrophilic parts of the protein were
determined according to the method of Chou and Fasman
(8). Several ATGs are located in the 5' part of the mRNAs.
The first two ATGs are almost immediately followed by stop
codons and therefore represent minicistrons known from
many eukaryotic and viral mRNAs (26). It is not known
whether they are used. The following two ATGs are both in
frame with the long ORF. Since the third ATG of the mRNA
is the first ATG of the long ORF and conforms as well to the
Kozak consensus sequence CC(A/G)CCATGC (25) as the
second one, translation probably starts here. The gB tran-
script is translated into a 928-aa protein (Fig. 5), which
shows characteristics of a glycoprotein. For the transport
into the endoplasmic reticulum, glycoproteins typically pos-
sess a signal peptide of 20 to 30 aa. The putative signal
peptide of MCMV gB consists of 39 aa with a hydrophobic
core from amino acids Ile-25 to Ile-36 (Fig. 5). The signal
peptide is probably cleaved after the predicted signal pepti-
dase recognition site Ala-37-Ala-38-Ala-39. In comparison
with the HCMV gB, the MCMV gB has a relatively long
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signal peptide of 39 aa. However, in comparison with the
signal peptides of the pseudorabies virus gB (36) and the
bovine herpesvirus type 1 gB (43), which consist of 53 and 67
predominantly hydrophilic aa, the MCMV gB signal peptide
is not unusual. The extracellular portion of the protein
following the signal peptide consists of 699 aa (Fig. 5,
Ser-40-Ser-739). Twelve potential N glycosylation sites are
located in this region (Fig. 5, overlined). The Chou-Fasman
analysis shows an extended hydrophobic region near the C
terminus of the gB, indicating a potential transmembrane
domain (data not shown). This putative transmembrane
region spans aa 740 to 804 (Fig. 5, boxed). The remaining,
basically hydrophilic aa 805 to 928 (Fig. 5) probably form the
cytoplasmic tail of the protein.
Comparison of the MCMV gB with the gB homologs of
other herpesviruses. To unequivocally demonstrate that the
identified gene is the gB homolog of MCMV, the deduced
amino acid sequence of the protein (Fig. 5, upper line) was
compared with the amino acid sequence of HCMV gB (Fig.
5, bottom line). The gB homologs of the HCMV strains
AD169 and Towne are composed of 906 (9) and 907 aa (39),
respectively. The MCMV gB and the HCMV gB have 45%
identical amino acids that are located mainly in the central
portion of the protein, while the N and C termini show little
or no identity (Fig. 5). Since all 11 cysteine residues follow-
ing the signal peptide are conserved (Fig. 5, asterisks), the
proteins probably possess similar tertiary structures. Eight
of the 12 potential N glycosylation sites of the MCMV gB are
found at the same positions as the glycosylation sites of the
HCMV gB (Fig. 5, underlined). The gB of HCMV is trans-
lated as a polyprotein and subsequently cleaved into two
subunits (21, 39). The potential cleavage sites of the HCMV
gB proteins are the motifs RTKR/STD463 (Towne) (39)
and RTRR/STS463 (AD-169) (21). A similar motif (RRKR/
SFD500) was detected in MCMV and probably represents the
proteolytic cleavage site.
The amino acid sequence of the MCMV gB protein was
also compared by dot matrix analysis with those of the gB
homologs of HCMV, Epstein-Barr virus (EBV) and HSV
type 1 (HSV-1) (Fig. 6). The MCMV protein is similar to all
other gB homologs, the transmembrane region being more
conserved than other parts of the protein. The highest degree
of homology exists between the gBs of MCMV and HCMV,
which have 45% of their amino acids in common. This was
expected, since the two betaherpesviruses are more related
to each other than to the alphaherpesviruses (HSV-1) and
gammaherpesviruses (EBV). The gB homologs of MCMV
and EBV and MCMV and HSV-1 show 34 and 26% identity,
respectively.
Identification of the MCMV glycoprotein B in infected cells.
To identify the gB gene products in infected cells, immuno-
precipitations were performed. Proteins of MCMV-infected
cells were labeled with [35S]methionine from 16 to 28 h p.i.
Proteins were precipitated from cell lysates by a monospe-
cific serum produced in a rabbit against the vaccinia virus
recombinant Vac-gB626. The autoradiography of the gel is
shown in Fig. 7A. The gB-specific serum precipitated poly-
peptides with apparent molecular masses of 130, 105, and 52
kDa from lysates of MCMV-infected cells but not from
lysates of noninfected cells (Fig. 7A, lanes 3 and 4). The
sizes of the proteins are similar to those reported for the
HCMV gB.
Expression of the MCMV gB ORF by a recombinant
vaccinia virus. Recombinant vaccinia viruses expressing the
MCMV gB ORF were constructed as described in Materials
and Methods. The acquisition of the MCMV DNA by the
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FIG. 6. Dot matrix comparison of the MCMV gB homolog and
the gB homologs of HCMV, EBV, and HSV-1. The following
parameters were used: window, 15 aa; and stringency, 12 aa. The N
termini of the sequences are in the bottom left-hand corner in each
graph.
recombinant vaccinia virus Vac-gB was verified by hybrid-
ization with a gB-specific DNA probe (data not shown). The
gB gene products synthesized in Vac-gB-infected CV-1 cells
were characterized by immunoprecipitation of [35S]methio-
nine-labeled cell proteins with a polyvalent anti-MCMV
serum. In Vac-gB-infected cells, a protein with the apparent
molecular mass of 130 kDa was found (Fig. 7B, lane 4),
which comigrated with the MCMV gB precursor (compare
Fig. 7A, lane 4 and Fig. 7B, lane 4).
Identity of the MCMV glycoprotein B with the MCMV
major envelope glycoprotein. The major envelope glycopro-
tein of MCMV has been described by Loh et al. (27, 28).
Three proteins, gp 150, gp 52, and gplO5, which were
derived from a common precursor of 128 kDa were identified
on the surface of the virion (27). This closely resembles the
situation described for the HCMV gB gene products. To test
whether the proteins of the major envelope glycoprotein
complex are the translation products of the identified gB
gene, the protein expressed by the recombinant vaccinia
virus Vac-gB was tested with the monoclonal antibody
2E8.21A against the major envelope glycoprotein (28). The
monoclonal antibody precipitated proteins of 130, 105, and
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FIG. 7. Detection of gB in MCMV- and Vac-gB-infected cells.
Proteins were labeled at 16 (MCMV) or 12 (Vac-gB) h p.i. for 12 h.
(A) Proteins of lysates from uninfected (lanes 1 and 3) or MCMV-
infected (lanes 2 and 4) cells were precipitated with preimmune
serum (lanes 1 and 2) or the gB-specific serum (lanes 3 and 4). (B)
Proteins of lysates from CV-1 cells infected with wild-type vaccinia
virus (lanes 1 and 3) or Vac-gB (lanes 2 and 4) were precipitated with
preimmune serum (lanes 1 and 2) or anti-MCMV serum (lanes 3 and
4). The molecular masses of the gB polypeptides are shown on the
left.
52 kDa from lysates of MCMV-infected cells (Fig. 8, lane 2).
Proteins of the same size were precipitated with the gB-
specific antiserum (Fig. 7A, lane 4). In Vac-gB-infected
cells, a protein which has the same molecular mass as that of
the gB precursor form was detected (Fig. 8, lane 4). Thus,
the glycoprotein B and the major envelope glycoprotein are
identical.
Induction of neutralizing antibodies by the Vac-gB recom-
binant. A gB-specific antiserum was raised in mice by
infection with the Vac-gB recombinant and tested for neu-
tralizing activity in a plaque reduction assay. A mouse
preimmune serum and an anti-MCMV serum raised in mice
by infection with MCMV were included in the plaque
reduction assay for comparison. Whereas the mouse preim-
mune serum was not able to neutralize the virus, the anti-gB
and anti-MCMV antisera showed considerable neutralizing
activity (Table 1). The anti-gB serum neutralized MCMV in
the presence of complement. The anti-MCMV serum
1 29 .. 4
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FIG. 8. Identity of the MCMV glycoprotein B with the MCMV
major envelope glycoprotein. Polypeptides in lysates from unin-
fected (lane 1), MCMV-infected (lane 2), wild-type vaccinia virus
(strain Copenhagen)-infected (lane 3), and Vac-gB-infected (lane 4)
cells were precipitated with the monoclonal antibody 2E8.21A. The
molecular masses of the gB polypeptides are indicated on the left.
TABLE 1. Neutralization of MCMV by different antisera
MCMV plaque reduction (%)'
Antiserum With Without
complement complement
Preimmune 0 (1:10) 0 (1:10)
Anti-gB 73 (1:200) 0 (1:10)
41 (1:400)
Anti-MCMV 65 (1:1,600) 70 (1:20)
36 (1:3,200) 36 (1:40)
Serum dilutions are indicated in parentheses. For neutralizing sera,
dilutions that give more than 50% and less than 50% plaque reduction are
shown.
showed a higher level of neutralizing activity and was also
capable of neutralizing the virus in the absence of comple-
ment, although the complement-independent neutralizing
activity was weak.
DISCUSSION
The MCMV glycoprotein B gene was identified, se-
quenced, and expressed by recombinant vaccinia virus. The
gene product in Vac-gB-infected cells showed the same
migration property as the gB precursor in MCMV-infected
cells. Although the mature gB subunits were not found in
Vac-gB-infected cells, mice immunized with the recombi-
nant developed antibodies that neutralized MCMV in vitro.
The identification of the MCMV gB gene was possible
because the gene is located in a conserved block of genes
(23). The genes for glycoprotein B, a putative transport
protein, and the major DNA-binding protein are organized in
exactly the same order in HCMV, EBV, and HSV-1. The
viral DNA polymerase gene is located downstream of the gB
gene in HCMV and EBV but not in HSV-1 (23). Since
MCMV is more related to HCMV than to other herpesvi-
ruses, the MCMV gB gene was expected to be located
upstream of the polymerase gene. Sequencing of this region
revealed an ORF of 2,784 nt.
The assumption that the identified ORF represents the gB
gene was further strengthened by the high degree of homol-
ogy between the deduced amino acid sequence of the puta-
tive MCMV gB homolog and the amino acid sequences of
the gB homologs of HCMV, HSV-1, and EBV. The highest
degree of homology was found between the gBs of the two
members of the betaherpesviruses, MCMV and HCMV.
Considerable homology to gBs of other herpesviruses,
e.g., alphaherpesviruses (HSV-1) and gammaherpesviruses
(EBV), was also found. The recently published sequence of
the carboxy terminus of the MCMV gB of strain K181 is
almost identical to our sequence, with the exception of some
amino acid exchanges and a small deletion of 7 aa at position
805 (13). These data indicate that the function of the gB
allows only subtle differences at certain positions. The
deletion might point to a less important region of the protein.
Comparisons of the amino acid sequences of all known gB
homologs show that a significant portion of the amino acid
sequence is conserved among all herpesviruses (9, 22). It has
also been reported previously that 10 cysteine residues are
perfectly aligned in all herpesvirus gB homologs (22). There-
fore, the tertiary structure of the proteins appears to be
conserved too. This notion is confirmed by the fact that the
gB homolog from one herpesvirus can functionally comple-
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ment the gB deficiency of another closely related virus (35).
Thus, the glycoprotein B, an essential protein, is highly
conserved throughout all herpesviruses not only with regard
to genome location, primary amino acid sequence, and
secondary and tertiary structure but also in its function.
The investigation of the expression kinetics of the MCMV
gB gene revealed a difference from that of HCMV. Whereas
Spaete et al. report the appearance of the gB mRNA of the
HCMV strain Towne as soon as 4 h p.i. and well in advance
of gB protein synthesis, the MCMV gB mRNA is not visible
until late in infection (39). Transcription of the MCMV gB
gene is blocked by the DNA replication inhibitor phosphono-
acetic acid. Thus, the MCMV gB gene is a true late gene and
there is no evidence for posttranscriptional regulation such
as that suggested for the HCMV gB gene (strain Towne) (39).
However, despite the different transcriptional patterns, the
expression of the protein is restricted to the late phase in
both viruses. In addition to the expected 3.3-kb gB-specific
transcript, two RNAs of higher molecular masses are visible.
The existence of additional, longer transcripts has also been
reported for the HCMV gB gene (39) and the HCMV and
MCMV polymerase genes (13, 24). It has been proposed that
these HCMV transcripts might represent read-through prod-
ucts of the gB transcript which would normally terminate at
the polyadenylation signal within the DNA polymerase-
coding region (24). Whether a similar situation exists for the
larger MCMV transcripts remains to be established.
To conduct in vivo protection experiments, the gB ORF
was engineered into vaccinia virus. At first, it was possible
to clone only part of the gB gene into a vaccinia virus
recombination plasmid. For unknown reasons, the whole gB
ORF could not be inserted into a commonly used vaccinia
virus recombination plasmid. Similar problems have been
reported elsewhere for the cloning of the HSV gB gene (5)
and the HCMV gB gene (29). These problems could be due
to a gene product which is toxic for the bacteria. Therefore,
instead of subcloning the gene, it was flanked by the vaccinia
virus sequences from recombination vectors pGS62 and
pCS43. The resulting recombination vector was based on the
low-copy-number plasmid pACYC177. Because of a copy
number of only 20 plasmids per bacterial chromosome (6),
the bacteria are probably able to tolerate small amounts of
the putative toxic gene product.
The protein expressed by the recombinant vaccinia virus
Vac-gB has the same size (130 kDa) as the gB precursor
protein in MCMV-infected cells. However, the subunits of
105 and 52 kDa, which are visible in MCMV-infected cells,
could not be detected in Vac-gB-infected cells. For the
HCMV gB, it has been proposed that a cellular protease
cleaves the protein (38), which probably belongs to the
subtilisinlike serine protease family (2). The putative cleav-
age site of the MCMV gB corresponds to the consensus
cleavage motif of these proteases. For vaccinia virus-ex-
pressed substrates, it has been shown that cleavage by this
serine protease family does not occur late in infection (3). In
fact, when Vac-gB-infected cells were labeled from 3.5 to 6.5
h after infection, faint traces of the processed gB subunits
could be detected (data not shown).
Immunization with the Vac-gB recombinant induced a
considerable level of neutralizing activity. However, the
neutralizing activity level of the anti-MCMV serum was
higher. It has been reported elsewhere that a significant
portion of the human humoral immune response against
HCMV is directed against the HCMV gB (4). Further
experiments will clarify whether the higher neutralizing
activity of the anti-MCMV serum is due to a titer of anti-gB
antibodies higher than that of the Vac-gB serum or whether
the anti-MCMV serum also contains neutralizing antibodies
against other MCMV proteins.
In MCMV-infected cells, three proteins with the apparent
molecular masses of 130, 105, and 52 kDa were detected with
an anti-gB serum. Thus, the products of the MCMV gB gene
have approximately the same sizes as their HCMV counter-
parts (4, 9, 39). In addition, the proteins have exactly the
same sizes as the proteins of the major envelope glycopro-
tein complex of MCMV (27, 28). The reactivity of the
monoclonal antibodies 2E8.21A and 8G5.21A (28) with the
Vac-gB gene product in Western blotting (data not shown)
and immunoprecipitations confirmed the identity between
the gB gene products and the major envelope glycoprotein
complex.
As outlined above, the herpesvirus gB homologs are
extremely conserved in several aspects. Thus, the MCMV
gB is suitable for studying the immune response against
glycoprotein B in a natural virus-host model. The Vac-gB
construct will enable us to study the protective potential of
this protein. This may be of interest in view of the use of the
glycoprotein B as a subunit vaccine.
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